Skip to main
PACB
PACB logo

PACB Stock Forecast & Price Target

PACB Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Pacific Biosciences of California Inc. is experiencing positive trends in the placement and utilization of its Revio sequencing platform, which bodes well for its near-term guidance and longer-term growth targets set for 2026. The company has demonstrated a strong organic growth profile while also engaging in strategic acquisitions, indicating a comprehensive approach to expanding its market presence. Despite potential conservatism in guidance due to macroeconomic uncertainties, management's belief in the company's ability to return to growth this year reinforces a favorable outlook for Pacific Biosciences.

Bears say

Pacific Biosciences of California Inc faces a negative outlook primarily due to anticipated stagnation in utilization and demand for its sequencing instruments, which could jeopardize its financial targets for 2026. Additionally, persistent demand weakness, particularly in China, and tightening research budgets pose significant risks to the company's revenue streams. The potential for competitors to develop superior products further exacerbates concerns about market share loss and its consequential impact on Pacific Biosciences's financial performance.

PACB has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacific Biosciences of California (PACB) Forecast

Analysts have given PACB a Buy based on their latest research and market trends.

According to 15 analysts, PACB has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacific Biosciences of California (PACB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.